---
schema_version: "secwatch.filing_event.v1"
accession: "0001789769-24-000077"
form_type: "8-K"
ticker: "TIL"
cik: "0001789769"
company_name: "Instil Bio, Inc."
filed_at: "2024-08-01T23:59:59+00:00"
generated_at: "2026-05-31T13:55:16.816610+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Instil Bio licenses bispecific and CTLA-4 antibodies from ImmuneOnco in deal up to $2.15B

## Summary
- SynBioTx (Instil subsidiary) gains exclusive license to IMM2510 (PD-L1/VEGF) and IMM27M (CTLA-4) outside Greater China.
- ImmuneOnco receives $10M upfront, up to $50M near-term payments, plus up to $2.1B in milestones.
- Royalties on net sales outside Greater China: single-digit to low double-digit percent.
- SynBioTx can terminate for convenience on 180 days' notice; termination rights for breach or patent challenge.
- ImmuneOnco retains development and commercialization rights within China, including Hong Kong, Macau, Taiwan.

## SEC filing metadata
- accession: 0001789769-24-000077
- form_type: 8-K
- ticker: TIL
- cik: 0001789769
- company_name: Instil Bio, Inc.
- filed_at: 2024-08-01T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1789769/000178976924000077/0001789769-24-000077-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1789769/000178976924000077/til-20240801.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001789769-24-000077
- JSON: https://secwatch.observer/filing/0001789769-24-000077.json
- Plain text: https://secwatch.observer/filing/0001789769-24-000077.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.